Development and validation of a simplified Stroke-Thrombolytic Predictive Instrument

Neurology

Volumn 85, Issue 11, 2015, Pages 942-949

  Kent, David M ^a   Ruthazer, Robin ^a   Decker, Carole ^b,c   Jones, Philip G ^b,c   Saver, Jeffrey L ^d   Bluhmki, Erich ^e   Spertus, John A ^b,c  

^a TUFTS UNIVERSITY   (United States)

^b SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

^c UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT; TISSUE PLASMINOGEN ACTIVATOR;

AGE; AGED; ARTICLE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; DIABETES MELLITUS; DISEASE SEVERITY ASSESSMENT; EXTERNAL VALIDITY; FEMALE; FIBRINOLYTIC THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NEUROLOGIC DISEASE ASSESSMENT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROBABILITY; STROKE THROMBOLYTIC PREDICTIVE INSTRUMENT; SYSTOLIC BLOOD PRESSURE; TIME TO TREATMENT; CEREBRAL HEMORRHAGE; DEVICES; MIDDLE AGED; PROCEDURES; RISK; STROKE; TREATMENT OUTCOME; VALIDATION STUDY;

AGED; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; MIDDLE AGED; RISK; STROKE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 84945943352     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000001925     Document Type: Article

References (34)

1. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995; 333:1581-1587.
2. Jauch EC, Saver JL, Adams HP, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013;44:870-947.
3. American College of Emergency Physicians; American Academy of Neurology. Clinical policy: use of intravenous tPA for the management of acute ischemic stroke in the emergency department. Ann Emerg Med 2013;61: 225-243.
4. Fonarow GC, Reeves MJ, Smith EE, et al. Characteristics, performance measures, and in-hospital outcomes of the first one million stroke and transient ischemic attack admissions in Get with the Guidelines-Stroke. Circ Cardiovasc Qual Outcomes 2010;3:291-302.
5. Strbian D, Meretoja A, Ahlhelm FJ, et al. Predicting outcome of IV thrombolysis-Dreated ischemic stroke patients: the DRAGON score. Neurology 2012;78:427-432.
6. Kent DM, Selker HP, Ruthazer R, Bluhmki E, Hacke W. The Stroke-Dhrombolytic Predictive Instrument: a predictive instrument for intravenous thrombolysis in acute ischemic stroke. Stroke 2006;37:2957-2962.
7. Konig IR, Ziegler A, Bluhmki E, et al. Predicting longterm outcome after acute ischemic stroke: a simple index works in patients from controlled clinical trials. Stroke 2008;39:1821-1826.
8. Ntaios G, Faouzi M, Ferrari J, Lang W, Vemmos K, Michel P. An integer-based score to predict functional outcome in acute ischemic stroke: the ASTRAL score. Neurology 2012;78:1916-1922.
9. Saposnik G, Kapral MK, Liu Y, et al. IScore: a risk score to predict death early after hospitalization for an acute ischemic stroke. Circulation 2011;123:739-749.
10. Weimar C, Ziegler A, Konig IR, Diener HC. Predicting functional outcome and survival after acute ischemic stroke. J Neurol 2002;249:888-895.
11. Saposnik G, Guzik AK, Reeves M, Ovbiagele B, Johnston SC. Stroke prognostication using age and NIH Stroke Scale: SPAN-100. Neurology 2013;80:21-28.
12. Brott T, Adams HP, Olinger CP, et al. Measurements of acute cerebral infarction: a clinical examination scale. Stroke 1989;20:864-870.
13. Uyttenboogaart M, Stewart RE, Vroomen PC, Luijckx GJ, De KJ. Utility of the Stroke-Dhrombolytic Predictive Instrument. J Neurol Neurosurg Psychiatry 2008;79:1079-1081.
14. National Institute of Neurological Disorders and Stroke (NINDS). NIH Stroke Scale (NIHSS): English Program, Globally Distributed by Health Care Point. 2006. Available at: http://www.nihstrokescale.org. Accessed March 31, 2015.
15. Fonarow GC, Pan W, Saver JL, et al. Comparison of 30-day mortality models for profiling hospital performance in acute ischemic stroke with vs without adjustment for stroke severity. JAMA 2012;308:257-264.
16. Tirschwell DL, Longstreth WT Jr, Becker KJ, et al. Shortening the NIH Stroke Scale for use in the prehospital setting. Stroke 2002;33:2801-2806.
17. Singer OC, Dvorak F, du Mesnil de Rochemont R, Lanfermann H, Sitzer M, Neumann-Haefelin T. A simple 3-item stroke scale: comparison with the National Institutes of Health Stroke Scale and prediction of middle cerebral artery occlusion. Stroke 2005;36:773-776.
18. Pocock SJ, Assmann SE, Enos LE, Kasten LE. Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems. Stat Med 2002;21:2917-2930.
19. Pocock SJ, Lubsen J. More on subgroup analyses in clinical trials. N Engl J Med 2008;358:2076-2077.
20. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008;359:1317-1329.
21. Sandercock P, Wardlaw JM, Lindley RI, et al. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the Third International Stroke Trial [IST-3]): a randomised controlled trial. Lancet 2012;379:2352-2363.
22. Dzialowski I, Hill MD, Coutts SB, et al. Extent of early ischemic changes on computed tomography (CT) before thrombolysis: prognostic value of the Alberta Stroke Program Early CT Score in ECASS II. Stroke 2006;37:973-978.
23. Kent DM, Hill MD, Ruthazer R, et al. Clinical-CT mismatch and the response to systemic thrombolytic therapy in acute ischemic stroke. Stroke 2005;36:1695-1699.
24. Clark WM, Albers GW, Madden KP, Hamilton S. The rtPA (alteplase) 0-Do 6-hour acute stroke trial, part A (A0276g): results of a double-blind, placebo-controlled, multicenter study. Thrombolytic Therapy in Acute Ischemic Stroke Study Investigators. Stroke 2000;31:811-816.
25. Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. Recombinant tissue-Dype plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA 1999;282:2019-2026.
26. Hacke W, Kaste M, Fieschi C, et al. Randomised doubleblind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 1998;352:1245-1251.
27. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008;27:157-172.
28. Steyerberg EW. Program for testicular cancer analyses: evaluate performance. 2009. Available at: http://download.lww. com/wolterskluwer-vitalstream-com/PermaLink/EDE/A/ EDE-2009-10-02-STEYERBERG-200726-SDC1.pdf. Accessed March 31, 2015.
29. R Core Team. R: A Language and Environment for Statistical Computing. Vienna: R Foundation for Statistical Computing; 2014. Available at: http://www.R-project.org. Accessed March 31, 2015.
30. Sun X, Ioannidis JP, Agoritsas T, Alba AC, Guyatt G. How to use a subgroup analysis: users' guide to the medical literature. JAMA 2014;311:405-411.
31. Rothwell PM, Mehta Z, Howard SC, Gutnikov SA, Warlow CP. Treating individuals 3: from subgroups to individuals: general principles and the example of carotid endarterectomy. Lancet 2005;365:256-265.
32. van Klaveren D, Vergouwe Y, Farooq V, Serruys PW, Steyerberg EW. Estimates of absolute treatment benefit for individual patients required careful modelling of statistical interactions. J Clin Epidemiol Epub 2015 Feb 27.
33. Bluhmki E, Chamorro A, Davalos A, et al. Stroke treatment with alteplase given 3.0-4.5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial. Lancet Neurol 2009;8:1095-1102.
34. Kent DM, Shah ND. Risk models and patient-centered evidence: should physicians expect one right answer? JAMA 2012;307:1585-1586.